Dapivirine Ring: Media Toolkit

Embargoed Until:

ET

In a milestone for women’s HIV prevention, the European Medicines Agency has issued a positive opinion for the dapivirine vaginal ring to reduce women’s HIV risk. Developed by the nonprofit International Partnership for Microbicides, the monthly ring is designed to help address women’s unmet need for new prevention products given the persistently high rates of HIV they face, especially in sub-Saharan Africa. The positive opinion marks an exciting step toward expanding women’s HIV prevention options with a discreet, long-acting method they can use privately, on their own terms.

Press Release

File Description
HTML Press Release
PDF Press Release

Additional Materials

File Description
Frequently Asked Questions
Fact Sheet

A Long-Acting Ring for Women’s HIV Prevention

Multimedia

Photo Credits

Hand(s) holding ring
Please attribute to: Andrew Loxley, courtesy of IPM

Women holding ring
Please attribute to: Courtesy of IPM

File Description
Digital Story

The Dapivirine Ring: Expanding Women’s Choices for HIV Prevention
Announcement Video

IPM’s founder and CEO Zeda Rosenberg discusses what the EMA’s positive opinion means for the dapivirine ring.
Partner Video

IPM’s partners react to the EMA’s positive opinion and reflect on what the ring would mean for women.

Photos